HDAC3 and metabolic disease: The present findings raise the possibility that NCoR/HDAC3/PGC1β complexes function as coactivators downstream of other pathways that utilize TRAF6 and/or ERK and have implications for the therapeutic applications of recently developed HDAC3-specific inhibitors in inflammatory and metabolic diseases.